Microbiology and infectious disease testing represent one of the largest and most dynamic application segments in IVD. The shift from traditional culture-based microbiology to molecular-based syndromic testing is accelerating, driven by the need for faster time-to-result, broader pathogen coverage from a single sample, and stewardship of antimicrobial therapy. BioFire Diagnostics received FDA 510(k) clearance for its FilmArray Gastrointestinal Panel Mid in January 2025. The IVD industry is witnessing a decisive shift from single-pathogen to syndromic testing panels that simultaneously detect multiple pathogens linked to a specific clinical syndrome. Antimicrobial resistance diagnostics — identifying resistant organisms including MRSA, CRE, and VRE directly from clinical samples — is a rapidly growing sub-segment driven by global AMR stewardship programs. COVID-19 demonstrated the critical role of IVD in outbreak response at population scale, creating permanent investment in rapid molecular infrastructure.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Microbiology and Infectious Disease IVD Market Size and Forecast 2025-2030 by Segment
• Syndromic Testing Panels — Respiratory, Gastrointestinal, Meningitis, and Blood Culture
• Molecular Microbiology — PCR-Based Pathogen Detection and Multiplex Panels
• Blood Culture and Bacteremia — Automated Systems and Rapid ID/AST
• Antimicrobial Resistance Diagnostics — MRSA, CRE, VRE, and Rapid AST
• Parasitology and Mycology — Malaria, Fungal Infection, and Tropical Disease Testing
• Outbreak Response Platforms — Rapid Molecular Infrastructure and Surge Capacity
• Competitive Landscape — bioMérieux, Hologic, BD, Roche, BioFire, and Cepheid
• Investment and Partnership Opportunities